ArticleFrontiers in endocrinology2026
Ovarian Rev-erbα: a central regulator of fertility following chronodisruption.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Circadian rhythm disruption caused by shift work, nutritional imbalance, and the stresses of modern life can alter hormone secretion, lead to menstrual irregularities, impair follicle development, and contribute to ovarian hypoplasia. The mechanistic role of circadian rhythm disruption in reproductive disorders has been thoroughly investigated. Nuclear receptors are known to play an important role in female reproduction and in maintaining pregnancy. Rev-erbα, a circadian nuclear receptor, is a key component of the circadian clock and helps sustain circadian rhythm. Materials and Methods: We evaluated the potential prophylactic and therapeutic functions of Rev-erbα in supporting female fertility by orchestrating a series of events that culminate in successful pregnancy. We generated a circadian rhythm-disrupted female mouse model to study fertility. Results: The Rev-erbα ligand SR9011 improved the fertility index in these circadian rhythm-disrupted female mice. Moreover, SR9011 treatment restored impaired ovarian follicular cell proliferation and division, regulated steroidogenesis and steroid hormone production, enhanced progesterone and melatonin secretion, and mitigated the adverse effects of circadian disruption on folliculogenesis. SR9011 also reduced follicular atresia and promoted follicle development in CR-disrupted mice. Rev-erbα is a key regulator influencing oocyte retrieval, as demonstrated in mice treated with the Rev-erbα antagonist SR8278. Discussion/Conclusion: These findings suggest that targeting Rev-erbα signaling and elucidating its mechanistic role in female reproduction could inform the development of more effective strategies for treating female infertility. As a sought-after druggable target, Rev-erbα has a broad range of potential therapeutic applications and has recently attracted considerable attention in the context of female infertility treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.